Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma.
Bárcena-Varela M, Caruso S, Llerena S, Álvarez-Sola G, Uriarte I, Latasa MU, Urtasun R, Rebouissou S, Alvarez L, Jimenez M, Santamaría E, Rodriguez-Ortigosa C, Mazza G, Rombouts K, San José-Eneriz E, Rabal O, Agirre X, Iraburu M, Santos-Laso A, Banales JM, Zucman-Rossi J, Prósper F, Oyarzabal J, Berasain C, Ávila MA, Fernández-Barrena MG. Bárcena-Varela M, et al. Among authors: oyarzabal j. Hepatology. 2019 Feb;69(2):587-603. doi: 10.1002/hep.30168. Epub 2019 Jan 4. Hepatology. 2019. PMID: 30014490
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma.
Rabal O, San José-Enériz E, Agirre X, Sánchez-Arias JA, de Miguel I, Ordoñez R, Garate L, Miranda E, Sáez E, Vilas-Zornoza A, Pineda-Lucena A, Estella A, Zhang F, Wu W, Xu M, Prosper F, Oyarzabal J. Rabal O, et al. Among authors: oyarzabal j. J Med Chem. 2021 Mar 25;64(6):3392-3426. doi: 10.1021/acs.jmedchem.0c02255. Epub 2021 Mar 4. J Med Chem. 2021. PMID: 33661013
Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis.
Barcena-Varela M, Paish H, Alvarez L, Uriarte I, Latasa MU, Santamaria E, Recalde M, Garate M, Claveria A, Colyn L, Arechederra M, Iraburu MJ, Milkiewicz M, Milkiewicz P, Sangro B, Robinson SM, French J, Pardo-Saganta A, Oyarzabal J, Prosper F, Rombouts K, Oakley F, Mann J, Berasain C, Avila MA, G Fernandez-Barrena M. Barcena-Varela M, et al. Among authors: oyarzabal j. Gut. 2021 Feb;70(2):388-400. doi: 10.1136/gutjnl-2019-320205. Epub 2020 Apr 23. Gut. 2021. PMID: 32327527
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.
Colyn L, Bárcena-Varela M, Álvarez-Sola G, Latasa MU, Uriarte I, Santamaría E, Herranz JM, Santos-Laso A, Arechederra M, Ruiz de Gauna M, Aspichueta P, Canale M, Casadei-Gardini A, Francesconi M, Carotti S, Morini S, Nelson LJ, Iraburu MJ, Chen C, Sangro B, Marin JJG, Martinez-Chantar ML, Banales JM, Arnes-Benito R, Huch M, Patino JM, Dar AA, Nosrati M, Oyarzábal J, Prósper F, Urman J, Cubero FJ, Trautwein C, Berasain C, Fernandez-Barrena MG, Avila MA. Colyn L, et al. Among authors: oyarzabal j. Hepatology. 2021 Jun;73(6):2380-2396. doi: 10.1002/hep.31642. Hepatology. 2021. PMID: 33222246
Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.
Rabal O, Sánchez-Arias JA, San José-Enériz E, Agirre X, de Miguel I, Garate L, Miranda E, Sáez E, Roa S, Martínez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J. Rabal O, et al. Among authors: oyarzabal j. J Med Chem. 2018 Aug 9;61(15):6546-6573. doi: 10.1021/acs.jmedchem.7b01925. Epub 2018 Jul 19. J Med Chem. 2018. PMID: 29890830
Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
Rabal O, San José-Enériz E, Agirre X, Sánchez-Arias JA, Vilas-Zornoza A, Ugarte A, de Miguel I, Miranda E, Garate L, Fraga M, Santamarina P, Fernandez Perez R, Ordoñez R, Sáez E, Roa S, García-Barchino MJ, Martínez-Climent JA, Liu Y, Wu W, Xu M, Prosper F, Oyarzabal J. Rabal O, et al. Among authors: oyarzabal j. J Med Chem. 2018 Aug 9;61(15):6518-6545. doi: 10.1021/acs.jmedchem.7b01926. Epub 2018 Jul 19. J Med Chem. 2018. PMID: 29953809
Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.
San José-Enériz E, Agirre X, Rabal O, Vilas-Zornoza A, Sanchez-Arias JA, Miranda E, Ugarte A, Roa S, Paiva B, Estella-Hermoso de Mendoza A, Alvarez RM, Casares N, Segura V, Martín-Subero JI, Ogi FX, Soule P, Santiveri CM, Campos-Olivas R, Castellano G, de Barrena MGF, Rodriguez-Madoz JR, García-Barchino MJ, Lasarte JJ, Avila MA, Martinez-Climent JA, Oyarzabal J, Prosper F. San José-Enériz E, et al. Among authors: oyarzabal j. Nat Commun. 2017 May 26;8:15424. doi: 10.1038/ncomms15424. Nat Commun. 2017. PMID: 28548080 Free PMC article.
Dual epigenetic modifiers for cancer therapy.
José-Enériz ES, Rabal O, Agirre X, Oyarzabal J, Prosper F. José-Enériz ES, et al. Among authors: oyarzabal j. Mol Cell Oncol. 2017 Jun 20;4(4):e1342748. doi: 10.1080/23723556.2017.1342748. eCollection 2017. Mol Cell Oncol. 2017. PMID: 28868353 Free PMC article.
Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome.
Rodriguez-Madoz JR, San Jose-Eneriz E, Rabal O, Zapata-Linares N, Miranda E, Rodriguez S, Porciuncula A, Vilas-Zornoza A, Garate L, Segura V, Guruceaga E, Agirre X, Oyarzabal J, Prosper F. Rodriguez-Madoz JR, et al. Among authors: oyarzabal j. PLoS One. 2017 Dec 27;12(12):e0190275. doi: 10.1371/journal.pone.0190275. eCollection 2017. PLoS One. 2017. PMID: 29281720 Free PMC article.
101 results